Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The antidiabetic potential of glucagon receptor antagonism presents an opportunity for use in an insulin-centric clinical environment. To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Lepr db/db and Lep ob/ob mice with REMD 2.59, a human monoclonal antibody and competitive antagonist of the glucagon receptor. As expected, REMD 2.59 suppresses hepatic glucose production and improves glycemia. Surprisingly, it also enhances insulin action in both liver and skeletal muscle, coinciding with an increase in AMP-activated protein kinase (AMPK)-mediated lipid oxidation. Furthermore, weekly REMD 2.59 treatment over a period of months protects against diabetic cardiomyopathy. These functional improvements are not derived simply from correcting the systemic milieu; nondiabetic mice with cardiac-specific overexpression of lipoprotein lipase also show improvements in contractile function after REMD 2.59 treatment. These observations suggest that hyperglucagonemia enables lipotoxic conditions, allowing the development of insulin resistance and cardiac dysfunction during disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
Holland, W. L., Miller, R. A., Wang, Z. V., Sun, K., Barth, B. M., Bui, H. H., Davis, K. E., Bikman, B. T., Halberg, N., Rutkowski, J. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2277 · Cited by 892 · cited 8×
“AMPK activation in cultured myotubes (Holland et al., 2011).”
BackgroundMethodSelf-citationThe metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Barouch, L. A., Berkowitz, D. E., Harrison, R. W., O’Donnell, C. P., & Hare, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000083716.82622.fd · Cited by 341 · cited 1×
“This strain is also reported to have impaired left ventricular function and remodeling (Aasum et al., 2002; Barouch et al., 2003).”
BackgroundThe Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272 · cited 1×
“On the other hand, Longuet and colleagues demonstrated that glucagon activates AMPK in isolated hepatocytes (Longuet et al., 2008).”
BackgroundCeramide is metabolized to acylceramide and stored in lipid droplets
Senkal, C. E., Salama, M. F., Snider, A. J., Allopenna, J. J., Rana, N. A., Koller, A., Hannun, Y. A., & Obeid, L. M. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.02.010 · Cited by 237 · cited 1×
“Recent work has suggested that these minimally studied sphingolipid metabolites partition with triglycerides and may be protective against ceramidemediated cellular distress (Senkal et al., 2017).”
BackgroundLIAO, Y., TAKASHIMA, S., MAEDA, N., OUCHI, N., KOMAMURA, K., SHIMOMURA, I., HORI, M., MATSUZAWA, Y., FUNAHASHI, T., & KITAKAZE, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.04.018 · Cited by 236 · cited 2×
“As AMPK has an established role in maintaining cardiac function and energetics (Kim and Dyck, 2015; Liao et al., 2005), we believe that the loss in AMPK activation during diabetes may be linked to the accumulation of ectopic lipids that is characteristic of various models of diabetic…”
BackgroundConarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224
Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199
Enhanced muscle insulin sensitivity after contraction/exercise is mediated by AMPK
Kjøbsted, R., Munk-Hansen, N., Birk, J. B., Foretz, M., Viollet, B., Björnholm, M., Zierath, J. R., Treebak, J. T., & Wojtaszewski, J. F. P. (2017) · Diabetes · doi:10.2337/db16-0530 · Cited by 178
Aasum, E., Belke, D. D., Severson, D. L., Riemersma, R. A., Cooper, M., Andreassen, M., & Larsen, T. S. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00226.2001 · Cited by 154 · cited 1×
“This strain is also reported to have impaired left ventricular function and remodeling (Aasum et al., 2002; Barouch et al., 2003).”
BackgroundWang, M.-Y., Yan, H., Shi, Z., Evans, M. R., Yu, X., Lee, Y., Chen, S., Williams, A., Philippe, J., Roth, M. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424934112 · Cited by 112
Self-citationOkamoto, H., Kim, J., Aglione, J., Lee, J., Cavino, K., Na, E., Rafique, A., Kim, J. H., Harp, J., Valenzuela, D. M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1011 · Cited by 100 · cited 2×
“, 2015), type 2 diabetic rodents, non-human primates (Okamoto et al., 2015; Yan et al., 2009), and recently, in type 1 diabetic subjects (Pettus et al.”
BackgroundResultGlucagon receptor antagonism induces increased cholesterol absorption
Guan, H.-P., Yang, X., Lu, K., Wang, S.-P., Castro-Perez, J. M., Previs, S., Wright, M., Shah, V., Herath, K., Xie, D., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060897 · Cited by 76 · cited 1×
“First-generation glucagon receptor antagonists were able to successfully lower glycemia, but they had unacceptable side effects, such as hyperlipidemia, elevated liver transaminase, and hypertension (Gu et al., 2010; Guan et al., 2015; Sammons and Lee, 2015).”
BackgroundHypothalamic CaMKKβ mediates glucagon anorectic effect and its diet-induced resistance
Quiñones, M., Al-Massadi, O., Gallego, R., Fernø, J., Diéguez, C., López, M., & Nogueiras, R. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.09.014 · Cited by 60
Cited by
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Knerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Glucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
“59 preserved fractional shortening and ejection fraction in the Lepr T2D mice model.(101) Furthermore, GCGR antagonism was also able to prevent declines in the early diastolic filling peak velocity/late filling”
BackgroundMethodInfluentialGandasi, N. R., Gao, R., Kothegala, L., Pearce, A., Santos, C., Acreman, S., Basco, D., Benrick, A., Chibalina, M. V., Clark, A., et al. (2024) · Diabetologia · doi:10.1007/s00125-023-06060-w · Cited by 31
Metadata
- Authors
- Sharma, A. X., Quittner-Strom, E. B., Lee, Y., Johnson, J. A., Martin, S. A., Yu, X., Li, J., Lu, J., Cai, Z., Chen, S., Wang, M.-Y., Zhang, Y., Pearson, M. J., Dorn, A. C., McDonald, J. G., Gordillo, R., Yan, H., Thai, D., Wang, Z. V., Unger, R. H., & Holland, W. L.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 22
- Issue
- 7
- Pages
- 1760-1773
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2787153479
- Cited by
- 71
- References
- 16
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.